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diagnosis of either leukemia, melanoma, or non-small cell lung cancer (NSCLC) 
and reported currently using a treatment for their condition were included in the 
analyses. Adherence was measured using the Morisky Medication Adherence 
Scale (MMAS-8) modified for use in oncology. Sociodemographics, health history, 
and health outcomes were also assessed. Descriptive analyses of adherence were 
conducted along with an assessment of the relationships between adherence 
and health outcomes. RESULTS: A total of 103 respondents were included in the 
analyses (n=42, 41, and 20 for leukemia, melanoma, and NSCLC, respectively). 
Most respondents were male (69.9%) and the mean age was 57.1 years (SD=15.79). 
Across the three tumor types 65.0% of respondents reported some form of non-
adherent behavior (71.4%, 58.5%, and 65.0% for leukemia, melanoma, and NSCLC, 
respectively). Pooling tumor types, patients who were non-adherent reported 
significantly worse mental health status compared with patients who were 
adherent (Mean=44.41 vs. 49.48, p<.05). Similar trends (though only marginally 
significant) were observed for hospitalizations (Mean=0.97 vs. 0.42, p=.11) and 
emergency room visits (Mean=1.18 vs. 0.25, p=.07) in the past six months. 
CONCLUSIONS: These results suggest a significant level of non-adherence 
among patients being treated for leukemia, melanoma, and NSCLC. Although 
statistical power was modest due to small sample size, preliminary results 
suggest a deleterious effect of non-adherence on health outcomes. As more oral 
targeted therapies emerge, an emphasis should be placed on improving 
adherence rates to maximize treatment benefit and reduce societal costs.  
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OBJECTIVES: The aim of our study was to evaluate a sample of the population’s 
knowledge on cervical smear test and HPV, also learn about the vaccine, 
attitudes towards screening, the appearance at screening or absence 
motivations. METHODS: A quantitative cross-sectional, questionnaire survey 
was carried out among the mothers of girls aged nine to fourteen years in the 
public school of Nagyatád town in September 2012. In total, 247 questionnaires 
were distributed, of which 186 proved to be evaluated. The χ2-test was performed 
as a statistical method besides 95% probability (p<0.05). The data analysis was 
performed with SPSS 20.0 programs. RESULTS: 96.2% of the respondent women 
have had cervical smear tests. Their average age was 20.92 years when they went 
for the first time for cervical cancer screening. 84.4% of respondent women 
reported annual visit for screening. 49.2% of respondent women last appeared in 
2012, while 40.2% in 2011 at gynecologist. College graduates were significantly (χ2 
= 13.785, p = 0.032) less likely to take part on screening over two years interval. 
Most of their knowledge on the prevention of cervical cancer obtained from 
television (67.7%), gynecologist (58.6%), Internet (47.8%) or newspapers (36%). 
Only 8.1% had heard of the disease in the form of lectures. CONCLUSIONS: 
Women reported a very high participation rate at cervical cancer screening. 
Although there is a three years screening interval in Hungary, most of the 
women in our study reported a two years or less screening interval.  
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OBJECTIVES: To elicit utility values for CML chronic phase health states (i.e. 
molecular response (MR), complete molecular response (CMR) [i.e. undetectable 
disease on treatment], treatment-free remission (TFR) and re-appearance of 
detectable disease (RDD) [i.e. relapse from treatment-free remission to molecular 
response requiring treatment]) from the general public in the UK. METHODS: 
Interviewer-administered time trade-off (TTO) and standard gamble (SG) utilities 
were elicited for four CML-related health states from a random sample of 235 
members of the general public in the UK, using health state descriptions 
validated by clinicians and members of the general public. RESULTS: 
Respondents’ mean age was 61 years and 47% were female. Mean utilities were: 
0.90 (TTO) and 0.72 (SG) for RDD, 0.94 (TTO) and 0.80 (SG) for MR, 0.96 (TTO) and 
0.85 (SG) for CMR and 0.97 (TTO) and 0.87 (SG) for TFR. SG values were all 
significantly lower than TTO values (p <0.001). TTO values for TFR and CMR were 
significantly different from that for RDD (p = 0.002). The SG value for TFR was 
significantly different from that for MR and RDD (p <0.001). Additionally, the SG 
value for MR was significantly different from that for CMR (p = 0.02) and RDD (p 
<0.001). Respondents’ preference values for any of the states were not affected by 
their demographics, except SG values elicited from males which were ~0.08 
higher than those from females (p <0.05). CONCLUSIONS: These findings 
suggests that level of response to treatment impacts on patients’ health-related 
quality of life in CML. Health states associated with a better outcome (e.g. TFR) 
were associated with a higher preference value than states with a poorer 
outcome (e.g. RDD). These utility values can be used to estimate quality-adjusted 
life years associated with different treatment options.  
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OBJECTIVES: To determine the relationship between a man’s current urinary and 
sexual function, qualitative valuations of future loss of function, and preferences 
for potential urinary and sexual impairment should he undergo screening or 
treatment for prostate cancer. METHODS: We elicited time-tradeoff utilities for 
prostate cancer treatment outcomes from 168 men. We performed logistic 
regression to (1) analyze the relationships between current function, valuation of 
future loss of function, and preferences, and (2) identify the relationship between 
the qualitative responses and the optimal decision of whether to undergo 
screening for prostate cancer as determined from a previously-published 
decision-analytic model. RESULTS: Current function was not related to 
impotence and urinary incontinence utilities. Importance of sexual function and 
anticipated adjustment to a loss of sexual function were strongly related to 
impotence utilities (P<0.05). Greater perceived difficulty adjusting to loss of 
bladder control, an anticipated function, was significantly related to 
incontinence utilities. Based on the multivariate analysis, significant predictors 
for the utility of severe incontinence were family income (OR=0.26 [CI 0.08-0.87] 
for income $20k-$70k and OR=0.11 [CI 0.01-0.70] for income >$70k, relative to 
income group <$20k), family history of prostate cancer (OR=2.85 [CI 0.96-8.45]), 
work status (OR=2.90 [CI 0.99-8.50]), and attitude toward needing to wear an 
incontinence pad (OR=6.47 [CI 0.76-54.4]). However, no variables were significant 
predictors for the complete impotence utilities. The importance of sexual 
functioning, with odds of 2.99 ([CI 1.28-6.95]), was a significant predictor of the 
optimal decision to screen. CONCLUSIONS: Current function and satisfaction are 
not necessarily useful as proxy measures of utility; however, anticipated 
difficulty adjusting to adverse health effects were highly related to preferences. 
Similarly, the importance of sexual functioning, a future preference, was related 
to the optimal decision, which validates our previously published decision-
analytic model.  
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OBJECTIVES: Excess weight is associated with poorer disease outcomes across 
various cancers. The current study examined health outcomes associated with 
obesity in respondents with and without cancer, addressing a lack of large-scale, 
population-based research including non-cancer comparison groups. METHODS: 
Among 71,149 U.S. 2012 NHWS respondents, 7,751 reported diagnosis with 
cancer: any/metastatic solid tumor, leukemia, lymphoma, breast, cervical, 
colorectal, ovarian, prostate, skin, uterine, other, small cell lung, and/or non-
small cell lung cancer. Cancer diagnosis and obesity (BMI≥30 vs. less) were 
crossed for analysis, resulting in 69,292 respondents (excluding 1,857 without 
BMI information): 2,745 obese versus 4,860 non-obese with cancer and 20,177 
obese versus 41,510 non-obese without cancer. Health outcomes included Work 
Productivity and Activity Impairment questionnaire-based measures (among 
employed-only for work productivity), and Mental and Physical Component 
Summary (MCS and PCS) scores and health utilities (SF-6D) from the SF-36v2. 
Bivariate tests of column proportions and means for categorical and continuous 
variables, respectively, compared measures across all groups. Multivariable 
(linear and negative binomial) generalized linear models assessed outcomes as a 
function of obesity, cancer diagnosis, their interaction, and sociodemographic 
and health behavior covariates of interest, plus Charlson comorbidity index (CCI) 
scores. RESULTS: Respondents with versus without cancer were older and had 
higher CCI (as did obese versus non-obese respondents), all p<0.05. Adjusting for 
covariates, obesity versus no obesity was associated (among those with cancer) 
with decreases in PCS (-3.61 points) and utilities (-0.030) and increases in 
presenteeism-related (20%), overall work (18%), and activity (24%) impairment, 
all p<0.05. CCI was associated with significant impairments across outcomes, all 
p<0.001. CONCLUSIONS: Among cancer-diagnosed respondents, obesity was 
associated with significant impairments. Obese respondents with cancer also 
had a higher rate of comorbidity. Obesity and a history of cancer may represent a 
”dual-risk” profile, suggesting the need for coordinated follow-up care and health 
promotion in this population.  
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OBJECTIVES: To evaluate the concordance between Neurocognitive function 
(NCF), Karnofsky performance status (KPS), quality of life and time trade-off 
(TTO) over time. METHODS: We retrospectively analyzed secondary data from a 
randomized study of 58 patients who completed tests determining TTO utility 
with each of three time horizons (10 years, 5 years, and 1 year), neurocognitive 
function (Hopkins Verbal Learning Test–Revised [HVLT-R] and Trail Making Test 
Part B), KPS score, and quality of life (Functional Assessment of Cancer Therapy–
Brain [FACT-BR]) and symptoms (MD Anderson Symptom Inventory–Brain Tumor 
[MDASI-BT]) at baseline and at predetermined intervals for 2 years. Multiple 
linear regression analyses were used to estimate the relationships between TTO 
utility and other outcome variables, including a time variable to capture within-
patient change over time. RESULTS: Significant but weak associations were 
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found between 10-year TTO utility and FACT-BR scores (p<0.01), 10-year TTO 
utility and MDASI-BT (Sleep) scores (p=0.039), 5-year TTO utility and FACT-BR 
scores (p<0.01), and 5-year TTO utility and MDASI-BT (Sleep) scores (p=0.039). 
NCF and KPS scores were not significantly associated with TTO utility. The 
analysis of within-patient changes over time indicated significant mean group 
increases in 10-year TTO utility (p=0.021) and NCF (HVLT-R Total Recall) scores 
(p=0.032); however, KPS score significantly decreased (p<0.01). CONCLUSIONS: 
Patients’ quality of life and sleep disturbance symptoms have significant but 
small effects on the patients’ willingness to trade time. The lack of correlation 
between TTO utility and functional status as well as cognitive function suggests 
that patients’ preferences for better health and for quantity of life are primarily 
influenced by the expected length of time until death and not by their current 
health state.  
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OBJECTIVES: To evaluate the quality of life (QoL) among women with cervical 
lesions using the EuroQol EQ-5D instrument to establish utilities of health states 
in mainland China. METHODS: Patients with cervical precursor lesions and 
cancer were recruited from the West China Second Affiliated Hospital between 
May 2010 and January 2011. They were surveyed with the EQ-5D prior to 
treatment, and at 1, 3 and 6 months after treatment. We calculated QoL scores 
through the five-item descriptive system of health states of the EQ-5D and the 
classic UK preference weighting system. RESULTS: A total of 194 women 
completed the questionnaire, including 78 with cervical precursor lesions, 85 
with early cervical cancer (FIGO Stage Ia, Ib and IIa), and 31 with advanced 
cervical cancer (FIGO stage IIb+).  Statistically significant differences were noted 
in QoL scores between different stages of cervical lesions (F=33.94, P<0.001) and 
between different time points (F=23.41, P<0.001). Pairwise comparisons showed 
that there was a consistent decline in the QoL scores in the spectrum of cervical 
lesions at each time point after treatment (all P<0.05). There existed an 
increasing trend in the timeline of treatment among women with cervical 
precursor lesions, though the QoL scores were not statistically different between 
3 and 6 months after treatment (P=0.099). For early cervical cancer, the QoL 
scores declined in the first month of treatment (P=0.057), and increased to a 
higher level than prior to treatment at 6 months (P<0.001). Despite a statistical 
difference between 1 and 6 months after treatment (P=0.016), advanced cervical 
cancer showed a similar secular trend. CONCLUSIONS: Women with early stage 
of cervical lesion have better QoL than those with late stage of disease. The QoL 
improves for cervical precursor lesions as treatment continues, while it declines 
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OBJECTIVES: Next generation genomic sequencing is a promising transformative 
technology; however, little is known about factors that influence patients’ 
preferences for the return of incidental findings that are likely to be an inevitable 
aspect of genome sequencing. The objective of this study was to identify the 
attributes of incidental findings important to patients and develop a discrete 
choice experiment (DCE) to quantify patient preferences. METHODS: An initial 
set of key attributes and levels was developed from a literature review and in 
consultation with experts. The attributes’ salience and comprehension were 
refined using focus groups (FG) (2 groups, N=12 total) and cognitive interviews 
(CI) (N=6) with patients who received genetic testing for familial colorectal cancer 
or polyposis syndromes. The attributes and levels used in the hypothetical 
choices presented to FG and CI participants were constructed using an 
orthogonal main-effects experimental design. RESULTS: Overall, we observed a 
wide range of preferences for genomic sequencing information; however, 
patients tended to focus on the importance of several consistent attributes in 
describing their preferences. The final DCE instrument incorporates the 
following attributes and levels: lifetime risk of developing the disease (5%, 40%, 
70%); disease treatability (medical intervention available, lifestyle intervention 
available, or none); disease severity (mild, moderate, severe); carrier status (yes, 
no); drug response likelihood (high, moderate, none), and out-of-pocket test cost 
($250, $425, $1000, $1900). CONCLUSIONS: Individual patient preferences for 
incidental genomic findings are likely influenced by a complex set of diverse 
attributes. This study identified an initial set of important factors, though further 
research is needed to explore preferences in different settings and to develop 
effective ways of helping patients and providers understand and address these 
preferences in the return of incidental findings. Measuring preferences using 
DCE instruments may facilitate patient-provider communication by quantifying 
patients’ personal utility for particular attributes of incidental findings.  
 
PCN103  
CHANGE IN PATIENT-REPORTED OUTCOMES DURING THE FIRST YEAR POST-
DIAGNOSIS OF MULTIPLE MYELOMA  
Pashos CL1, Shah JJ2, Terebelo HR3, Durie BG4, Abonour R5, Gasparetto C6, Mehta J7, 
Narang M8, Thomas S9, Toomey K10, Swern A11, Sullivan KA11, Street TK11, Khan ZM11, 
Nourbakhsh A11, Hardin JW12, Wildes TM13, Rifkin RM14 
1United BioSource Corporation, Lexington, MA, USA, 2MD Anderson Cancer Center, Houston, TX, 
USA, 3Newland Medical Associates, Novi, MI, USA, 4International Myeloma Foundation (IMF) 
and Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA, 5Indiana University 
Simon Cancer Center, Indianapolis, IN, USA, 6Duke University Medical Center, Durham, NC, 
USA, 7Northwestern University, Chicago, IL, USA, 8Maryland Hematology Oncology, 
Westminster, MD, USA, 9Illinois Cancer Care, Peoria, IL, USA, 10Steeplechase Cancer Center, 
Somerville, NJ, USA, 11Celgene Corporation, Summit, NJ, USA, 12University of South Carolina, 
Columbia, SC, USA, 13Washington University Medical School, St. Louis, MO, USA, 14US Oncology, 
Denver, CO, USA  
OBJECTIVES: To identify possible changes in patient-reported outcomes (PRO), 
including health-related quality of life (HRQoL), of multiple myeloma (MM) 
patients undergoing treatment in the USA. PRO of those meeting CRAB criteria 
(hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) for 
active/symptomatic MM was assessed at baseline and 1 year post-baseline. 
METHODS: Data were collected in Connect® MM, an ongoing prospective US 
disease registry of MM patients. Clinicians reported patient demographics and 
clinical characteristics. PRO were recorded at baseline, within 2 months of 
diagnosis, and 1 year post-baseline by completing Brief Pain Inventory (BPI), EQ-
5D, and Functional Assessment of Cancer Therapy (FACT)-MM questionnaires. 
Mean (± standard deviation) BPI, EQ-5D, and FACT-MM change scores were 
analyzed. Statistical significance was assessed. RESULTS: Overall, 636 patients 
(from 189 centers) meeting CRAB criteria provided data at baseline and 1 year 
post-baseline. The majority of patients were male (58%), white (84%), with a 
mean age of 66 (±11) years. Patients were seen in academic (17%), community 
(81%), or government (2%) clinical centers. Evaluable International Staging 
System stages were: I (29% of patients); II (35%); and III (35%). Average pain 
improved over 1 year (P < 0.0005). HRQoL/functional ability improved in 4 of 5 
FACT domains (except social/family; all others P < 0.0001), and in 4 of 5 EQ-5D 
domains (except pain/discomfort; all other P values ranged from 0.0142 to  
< 0.0001). Overall HRQoL, as shown by FACT-MM and FACT-General total scores, 
also improved (both P< 0.0001). Overall HRQoL improved in males and females, 
and in younger age groups (<65 and 65–74 years), but not in those ≥ 75 years. 
CONCLUSIONS: Connect® MM findings indicate that most PRO improved 
between baseline and 1 year post-baseline. Data will be examined to identify 
which disease- and treatment-related factors are associated with HRQoL 
improvement in this MM population.  
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OBJECTIVES: Existing measures of opioid-induced constipation (OIC) symptoms 
have not been developed in accordance with FDA’s 2009 Guidance for Patient-
Reported Outcome (PRO) Measures. The OIC Rating Scale (ORS) was developed 
based on literature and comprehensive qualitative research. This study aimed to: 
1) validate a conceptual framework of two domains; 2) determine the optimal 
scoring system; 3) examine item- and scale-level psychometrics; and 4) establish 
domain responder definitions (RD). METHODS: ORS was administered to 215 US 
adults with OIC in a Phase II study. Confirmatory factor analysis (CFA) was used 
to test the fit of the previously developed conceptual framework. The evaluation 
analyzed data from the 2-week baseline period and the 5-week treatment period. 
Item response theory (IRT) was used to determine an optimal scoring approach, 
followed by classical psychometrics including item- and scale-level reliability, 
and convergent validity. Distribution- and anchor-based approaches were used 
to determine the RD for each domain based on week 5 change from baseline. 
RESULTS: Based on descriptive statistics, item-level correlations, and CFA results 
(confirmatory fit index/non-normed fit index >0.96, standardized root mean 
residual <0.04), a two-domain structure of the ORS was validated and carried 
forward in tests of reliability (αs > 0.85, test-retest ICCs >0.60) and validity 
analyses (convergent rs 0.37-0.55), and to establish score interpretation. IRT 
results provided no compelling evidence requiring special item weights rather 
than a simple raw sum-score per domain. The two-item bowel movement 
symptom (BMS) domain RD = 2 and six-item gastrointestinal-related symptom 
(GRS) domain RD = 4. CONCLUSIONS: The ORS instrument demonstrated strong 
psychometric characteristics using analyses following the current FDA guidance 
for PRO measures. The two domains explained the correlations among the bowel 
movement and gastrointestinal-related symptoms in OIC. These results support 
further use of this instrument in studies of potential treatments for OIC.  
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OBJECTIVES: Metastatic castration-resistant prostate cancer (mCRPC) continues 
to be an aggressive and life-threatening cancer. With approved drugs providing 
only modest survival benefits, there is an increasing interest on improving 
symptoms and health-related quality of life (HRQoL). The aim of this review is to 
understand the impact of mCRPC treatments on HRQoL. METHODS: The search 
was conducted on PubMed®. Additional articles were found from cross-
referencing, and on ASCO and ESMO websites. A multi-step approach ensured 
that a wide range of mCRPC studies were reviewed. The search was limited to 
